Stock Evaluator: Kamada Ltd. (KMDA)

Kamada Ltd. KMDA

$7.83 -0.10 -1.26%
November 19, 2026 2:16:02 PM EST November 10, 2021 Volume: 115,119
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Commentary & Analysis


Financial Summary

Share Statistics KMDA Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $476.0 $213.9 38%
Shares Out (Mil) 57.1 55.4 50%
Institutional Ownership 82.1% 93.3% 50%
Float (Mil) 33.1 40.6 38%
Beta 0.20 0.98 12%
Avg Daily Volume (000s) 139 597 40%
Price Change
(52-week)
18.0% 40.9% 67%
Growth KMDA Industry
Median
Percentile
(All Stocks)
Sales (5yr) 6.3% 13.2% 43%
Net Income (5yr) 3.4% (10.7%) 45%
EPS (5yr) (1.6%) 15.5% 29
Dividends (5yr) 0.0% 0.0% 70%
Cash Flow (5yr) (15.8%) (15.7%) 46%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 4 3 3
Current EPS $0.110 $0.473 $0.580
Month Ago EPS $0.120 $0.478 $0.577
# Rev Up 1 0 0
# Rev Down 0 1 1
Three Months Ago EPS $0.125 $0.488 $0.597
Year/Year Chg (21.4%) 35.1% 87.7%
Financials KMDA Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $197 $39 31%
Net Income (TTM) (Mil) $25 ($44) 49%
EPS (TTM) $0.430 ($1.400) 51%
Operating Cash Flow (TTM) (Mil) $45 ($34) 45%
Net Cash Flow (TTM) (Mil) $3 $-0 52%
Long-Term Debt (Q1) (Mil) $9 $4 28%
Enterprise Value (Q1) (Mil) $407 $135 33%
Valuation KMDA Industry
Median
Percentile
(All Stocks)
P/B 1.72 1.97 50%
P/E 18.8 17.6 52%
Dividend Yield 3.5% 0.0% 87%
PEG (5yr hist) na 0.8 na
Ratios KMDA Industry
Median
Percentile
(All Stocks)
Gross Margin 41.6% 67.9% 52%
Net Margin 12.7% (50.8%) 68%
ROA 6.6% (47.5%) 77%
ROE 9.4% (51.9%) 54%
Liabilities to Assets 29.9% 29.7% 21%
F-Score 8 3 93%

Kamada Ltd. did not pass any screens on 11/18/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors